stockrow
Friday 6 November 2026
Export PRAX’s income statement to Excel — free account
Praxis Precision Medicines, Inc.
PRAX Healthcare Biotechnology
Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.
- Revenue
- +1,349.1%
- EPS
- +13.3%
- Free cash flow
- −43.5%
Quarter to June 2026, against a year earlier
276.75
14.16
+5.39%
Follow PRAX
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(75.20%) | (45.83%) | (35.32%) | (38.86%) | |
| (67.20%) | (42.68%) | (33.68%) | (36.80%) | ||
ROIC |
(239.95%) | (73.12%) | (35.84%) | (40.58%) | |
Return on Tangible Assets |
(123.47%) | (55.01%) | (43.67%) | (46.88%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(10.42) | (11.07) | (9.77) | (10.51) | |
Free Cash Flow |
(228.97) | (249.17) | (282.33) | (306.16) | |
Capital Expenditures |
(0.11) | (0.11) | (0.12) | (1.08) | |
| Other line items | |||||
Cash ROIC |
(37.50%) | (16.86%) | (12.85%) | (14.58%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.84 | 0.82 | 0.86 | 0.90 | |
Depreciation/Fixed assets |
(23.86) | (23.48) | (16.98) | (5.29) | |
Capex/Depreciation |
0.03 | 0.03 | 0.04 | 0.42 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(10.41) | (11.07) | (9.77) | (10.47) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.04) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026